bepirovirsen

From Aaushi
Jump to navigation Jump to search

Indications

* sustained HBsAg & HBV DNA loss in 9- 10% of patients

Dosage

  • 300 mg per week for 24 weeks

Mechanism of action

More general terms

Additional terms

References

  1. Yuen M-F et al. Efficacy and safety of bepirovirsen in chronic hepatitis B infection. N Engl J Med 2022 Nov 8; [e-pub]. PMID: https://www.ncbi.nlm.nih.gov/pubmed/36346079 https://www.nejm.org/doi/10.1056/NEJMoa2210027
    Hoofnagle JH. A modern therapy for an ancient disease. N Engl J Med 2022 Nov 8; [e-pub]. PMID: https://www.ncbi.nlm.nih.gov/pubmed/36346068 https://www.nejm.org/doi/10.1056/NEJMe2213449